The Denali Approach

Denali’s approach to developing therapies is based on the following three principles

Understanding the Impact of Genetics

There have been recent discoveries of genes that are associated with neurological conditions, such as Parkinson’s disease. These discoveries have advanced our understanding of neurodegeneration—the biological changes that result in death and dysfunction of brain cells and cells that support them.

Denali is applying deep scientific and drug development expertise to discover and develop therapies that slow or stop neurodegeneration.

Improving Delivery of Medications to the Brain

The human brain contains approximately 400 miles of blood vessels. These blood vessels are lined by closely linked cells to form the Blood-Brain Barrier (BBB).

The BBB protects the brain by filtering out toxins, as well as other substances.

Developing therapeutics that cross the BBB has been a major obstacle to successful drug development for neurodegenerative diseases.

Development of drugs that cross the BBB is critical to achieving effective treatments for Parkinson's disease.

Denali is focused on developing medications that are capable of passing through the BBB to achieve levels in the brain sufficient to have the desired therapeutic effect.

Using Biomarkers to Guide Development of Therapies

Denali uses biological markers (biomarkers) found in tissues or body fluids, such as blood, to look for signs of abnormal condition or disease.

How Denali uses biomarkers

  • Monitor the effects of investigational medications for Parkinson’s disease.
  • Identify the patients that may have the highest likelihood of responding to our therapeutics.
  • Inform dose selection for our clinical trials.

Clinical Trials

Learn more about Denali clinical trials for Parkinson’s Disease

Go Now